- Home
- SFL vs PCRX Comparison
SFL vs PCRX Comparison
Compare SFL & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- PCRX
- Stock Information
- Founded
- SFL 2003
- PCRX 2006
- Country
- SFL Bermuda
- PCRX United States
- Employees
- SFL N/A
- PCRX N/A
- Industry
- SFL Marine Transportation
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SFL Consumer Discretionary
- PCRX Health Care
- Exchange
- SFL Nasdaq
- PCRX Nasdaq
- Market Cap
- SFL 1.1B
- PCRX 1.2B
- IPO Year
- SFL N/A
- PCRX 2011
- Fundamental
- Price
- SFL $8.09
- PCRX $26.07
- Analyst Decision
- SFL Strong Buy
- PCRX Buy
- Analyst Count
- SFL 1
- PCRX 6
- Target Price
- SFL $13.00
- PCRX $30.00
- AVG Volume (30 Days)
- SFL 1.3M
- PCRX 599.4K
- Earning Date
- SFL 11-05-2025
- PCRX 11-05-2025
- Dividend Yield
- SFL 13.33%
- PCRX N/A
- EPS Growth
- SFL N/A
- PCRX N/A
- EPS
- SFL 0.26
- PCRX N/A
- Revenue
- SFL $852,528,000.00
- PCRX $705,848,000.00
- Revenue This Year
- SFL N/A
- PCRX $7.36
- Revenue Next Year
- SFL $3.16
- PCRX $10.07
- P/E Ratio
- SFL $30.89
- PCRX N/A
- Revenue Growth
- SFL 3.21
- PCRX 2.25
- 52 Week Low
- SFL $6.78
- PCRX $13.42
- 52 Week High
- SFL $11.85
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- SFL 42.14
- PCRX 51.80
- Support Level
- SFL $7.93
- PCRX $26.22
- Resistance Level
- SFL $8.31
- PCRX $27.50
- Average True Range (ATR)
- SFL 0.16
- PCRX 0.93
- MACD
- SFL 0.01
- PCRX -0.14
- Stochastic Oscillator
- SFL 35.56
- PCRX 21.89
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.